Suppr超能文献

管腔型乳腺癌的组织学

Histology of Luminal Breast Cancer.

作者信息

Erber Ramona, Hartmann Arndt

机构信息

Institute of Pathology, University Hospital Erlangen, Friedrich Alexander University Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.

出版信息

Breast Care (Basel). 2020 Aug;15(4):327-336. doi: 10.1159/000509025. Epub 2020 Jul 15.

Abstract

BACKGROUND

Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.

SUMMARY

IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.

KEY MESSAGES

Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.

摘要

背景

浸润性乳腺癌(IBC)可通过基因表达谱分析分为预后和预测分子亚型(包括管腔型乳腺癌)。管腔型IBC包含多种具有不同临床和病理特征的组织学亚型。

总结

非特殊亚型的IBC是一般情况下最常见的组织学亚型,在管腔型IBC中也是如此。经典浸润性小叶癌通常聚集在管腔亚组中,其特征是细胞间黏附丧失和E-钙黏蛋白表达缺失。少见的、形态学上不同的管腔型IBC亚型包括管状癌、浸润性筛状癌、黏液癌和浸润性微乳头状癌。具有顶泌汗腺分化的乳腺癌,具有雄激素受体(AR)的特征性表达,通常聚集在管腔AR类别中。很少能见到乳腺神经内分泌肿瘤。男性乳腺的IBC通常与管腔型亚型相符。

关键信息

独立于组织学亚型之外,浸润性乳腺癌(IBC)可根据mRNA基因表达水平分为分子亚型。利用这种分子分型,基于基因表达谱(针对激素受体阳性、HER2阴性IBC建立)、分级和Ki-67指数的风险评分,可以预测管腔型乳腺癌患者的预后和对化疗的反应。在常规诊断中,雌激素受体(ER)和孕激素受体(PR)的表达、HER2状态以及增殖率(Ki-67)用于确定替代(分子样)亚型。在管腔样IBC中,非特殊亚型和浸润性小叶癌是最常见的组织学亚型。其他罕见的组织学亚型(如管状癌)因其独特的临床和病理特征应予以识别。

相似文献

1
Histology of Luminal Breast Cancer.
Breast Care (Basel). 2020 Aug;15(4):327-336. doi: 10.1159/000509025. Epub 2020 Jul 15.
3
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Ann Oncol. 2014 Feb;25(2):384-91. doi: 10.1093/annonc/mdt525. Epub 2013 Dec 18.
6
Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast.
Rev Bras Ginecol Obstet. 2013 Mar;35(3):97-102. doi: 10.1590/s0100-72032013000300002.
7
Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update.
Arch Pathol Lab Med. 2016 Aug;140(8):806-14. doi: 10.5858/arpa.2015-0133-RA.
8
Invasive breast cancer: a significant correlation between histological types and molecular subgroups.
J Cancer Res Clin Oncol. 2013 Apr;139(4):617-23. doi: 10.1007/s00432-012-1365-1. Epub 2012 Dec 27.

引用本文的文献

1
From Breast to Eye: A Rare Case of Ocular Metastasis From Luminal Breast Cancer in a Nicaraguan Patient.
Cureus. 2025 Mar 17;17(3):e80748. doi: 10.7759/cureus.80748. eCollection 2025 Mar.
3
ALLSTAR: Inference of ReliAble CausaL RuLes between Somatic MuTAtions and CanceR Phenotypes.
Bioinformatics. 2024 Jul 22;40(7). doi: 10.1093/bioinformatics/btae449.
4
Contrast-enhanced ultrasound for the preoperative prediction of pathological characteristics in breast cancer.
Front Oncol. 2024 Feb 29;14:1320714. doi: 10.3389/fonc.2024.1320714. eCollection 2024.
7
Role of EGFR and FASN in breast cancer progression.
J Cell Commun Signal. 2023 Dec;17(4):1249-1282. doi: 10.1007/s12079-023-00771-w. Epub 2023 Jul 25.
8
Potential Antitumor Effect of α-Mangostin against Rat Mammary Gland Tumors Induced by LA7 Cells.
Int J Mol Sci. 2023 Jun 17;24(12):10283. doi: 10.3390/ijms241210283.

本文引用的文献

1
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
2
Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients.
Eur J Breast Health. 2019 Nov 20;16(1):39-43. doi: 10.5152/ejbh.2019.4997. eCollection 2020 Jan.
5
Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis.
Clin Breast Cancer. 2018 Oct;18(5):e997-e1002. doi: 10.1016/j.clbc.2018.06.013. Epub 2018 Jun 27.
7
Neuroendocrine Tumors of the Breast.
Arch Pathol Lab Med. 2017 Nov;141(11):1577-1581. doi: 10.5858/arpa.2016-0364-RS.
8
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验